ARTICLE | Company News

Pfenex, Leidos Holdings Inc., National Institutes of Health infectious news

January 6, 2014 8:00 AM UTC

On Dec. 17, 2013, Pfenex said it will provide its recombinant protective antigen ( rPA) immune-enhancing adjuvant under a sub-contract with Leidos to develop a next-generation anthrax vaccine. NIH's National Institute of Allergy and Infectious Diseases (NIAID) awarded the prime contract to Leidos, a national security, health and engineering solutions company. ...